Quarterly ResultMay 14, 2026, 04:15 PM
AEON Biopharma Q1 Results; FDA Supports ABP-450 Strategy; Debt Cut 90%
AI Summary
AEON Biopharma reported its first quarter 2026 financial results, including a net loss of $(11.793) million, a decrease from a net income of $9.095 million in Q1 2025. The company announced positive feedback from its FDA Type 2a meeting, supporting the analytical similarity strategy for its ABP-450 biosimilar program. AEON also significantly strengthened its balance sheet by completing a $6 million PIPE financing and a Daewoong note exchange, reducing outstanding debt by over 90%. Additionally, John Bencich was appointed as the new Chief Financial Officer, and the company's cash and cash equivalents of $6.2 million as of March 31, 2026, are expected to fund operations into Q3 2026.
Key Highlights
- FDA Type 2a meeting supported ABP-450's analytical similarity strategy for biosimilar pathway.
- Completed $6 million PIPE financing and Daewoong note exchange.
- Reduced outstanding debt by over 90% to $1.542 million from $34.600 million.
- Appointed John Bencich as Chief Financial Officer.
- Reported Q1 2026 net loss of $(11.793) million, compared to $9.095 million net income in Q1 2025.
- Cash and cash equivalents were $6.2 million as of March 31, 2026.
- Research and development expenses increased to $2.034 million in Q1 2026.